CNS Pharmaceuticals Inc. CNSP Archives - Page 4 of 22

MondayOct 16, 2023 12:35 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, the article points out that currently, glioblastoma has no cure and, because it is a highly invasive tumor, complete surgical removal is difficult. “Even with aggressive treatment, the cancer tends to recur, leading to a grim prognosis,” the article states. “The high mortality rate of…

WednesdayOct 11, 2023 1:32 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including…

MondaySep 25, 2023 10:30 am

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end The company is also preparing the interim study analysis for release by year’s end, now that more than 50 percent of the planned patient roster has reached a point necessary for effective comparison of performance of the flagship drug, Berubicin, to that of a standard of care chemotherapy agent The company has stated that…

FridaySep 15, 2023 12:10 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. “Most notably, this novel anthracycline demonstrated its capability to be a safe and innovative potential treatment option for GBM, having shown aspects integral to effective therapy for the disease… So far, 151 patients have been enrolled in the clinical study, with 105 set on Berubicin while the remaining 46 will be on Lomustine. This marks…

FridaySep 08, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study

CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM 151 patients have been enrolled in the study, marking the data cutoff point and a significant milestone toward reporting topline results before the end of the year Based on the results seen preclinically, the company remains optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a…

ThursdaySep 07, 2023 4:55 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (“GBM”), an aggressive and incurable form of brain cancer. “As we have noted previously, patient volunteers and their treating clinicians are the backbone of our Berubicin development program. We are deeply sensitive to the fact that these brave patients are facing the battle of their lives and we…

TuesdaySep 05, 2023 11:46 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS Pharmaceuticals CEO Climaco is scheduled to present during the two-day conference; his live webcast presentation is scheduled for Wednesday, Sept. 13, at 10:30 a.m. ET. In addition to the presentation, key CNPS officials will be available to participate in in-person and virtual one-on-one meetings with…

MondayAug 14, 2023 12:50 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date since we launched CNS Pharma. We are just a few months away from reporting topline results from our Berubicin potentially pivotal study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach…

MondayAug 07, 2023 1:03 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities

CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly. Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a phase I trial in 2006, including one patient whose…

ThursdayAug 03, 2023 12:44 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the study, with 180 patients of the 243 expected currently enrolled across 46 clinical trial sites. In addition, CNS has documented the necessary number of patients reaching the primary efficacy endpoint, or overall survival, to conduct…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP